Take Advantage of Biogen Idec’s Weakness
Long Ideas - Since reaching a high of over $240 in late May, shares of Biogen Idec (BIIB) have pulled back, falling nearly 18% amidst broader volatility in … Continue Reading
Read NowMost Popular
Amarin’s News Flow Adds Fuel to the Fire
Long Ideas - Amarin (AMRN) announced Friday morning that a Phase I trial comparing the bioavailability of components from a fixed-dose combination of Vascepa plus rosuvastatin, to concomitant … Continue Reading
Read NowMedivation’s Competitor Was Just Acquired, but It’s Not as Bad As It Sounds
Long Ideas - Shares of Medivation (MDVN) fell sharply on Monday June 17, closing down over 6% on news that Johnson & Johnson (JNJ) has acquired Aragon Pharmaceuticals … Continue Reading
Read NowWall Street Initiation on Synergy Pharma Gets The Stock Moving
Long Ideas - Synergy Pharmaceuticals (SGYP) is well-funded, with over $100 million in cash after its last capital raise, and the weakening biotech tape of late enables investors … Continue Reading
Read NowGood News for this Small-Cap Biotech: Eli Lilly Wants to Develop its Diabetes Drug
Long Ideas - Large-cap drug company Eli-Lilly (LLY) must have liked what it saw in April when Transition Therapeutics (TTHI) reported its Phase Ib proof-of-concept results for TT-401, … Continue Reading
Read NowEight Trade Ideas and A Recap of our Latest
Most Popular - Vascepa’s commercial prospects are one of the hottest topics of debate in biotechnology, and this week PropThink outlined why you can trade Amarin (AMRN) in … Continue Reading
Read NowPharmacyclics’ Recent Selloff Was Wrong: Here’s Why We’re Involved
Long Ideas - Although Infinity Pharmaceuticals’ (INFI) post-ASCO selloff, which we discussed on Monday, was perhaps the most prominent ASCO demolition, it wasn’t the only unwarranted decline. Shares … Continue Reading
Read Now